A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients

NCT00782717 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

263

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Edema

Interventions

DRUG: Nepafenac ophthalmic suspension, 0.1% (NEVANAC)
OTHER: Nepafenac ophthalmic suspension vehicle
DRUG: Prednisolone acetate ophthalmic suspension (OMNIPRED)

Sponsor

Alcon Research